Key result
Vasodilators have variable effects on renal function in acute heart failure, with agents like levosimendan and serelaxin showing potential renoprotective benefits, while data for nitrates remain limited.
Why the study?
Do vasodilators improve or worsen renal function in patients with acute heart failure?
Do vasodilators improve or worsen renal function in patients with acute heart failure?
The review emphasizes that while vasodilators are standard therapy for AHF, their impact on renal function is complex and requires careful hemodynamic monitoring, with some newer agents showing promise for organ protection.
Vasodilator therapy is common in acute heart failure (AHF) patients, although evidence for morbidity and mortality benefits is limited for many of these drugs. AHF is frequently accompanied by renal dysfunction, which is a strong, independent predictor for poor prognosis. Several hemodynamic and neurohormonal effects of vasodilators—including preload and afterload reduction, activation or inhibition of neurohormonal and inflammatory cascades—have the potential to modulate cardiorenal interaction and impact renal function. However, the effect of vasodilators on renal function in acute heart failure is often poorly described. In this review, we provide an overview of the known cardiorenal effects of traditional and novel vasodilators in patients with acute heart failure.
No takes yet. Share an insight, caveat, or question.
Valente et al. (2013) conducted a review in Acute heart failure. Vasodilators was evaluated. Vasodilators have variable effects on renal function in acute heart failure, with agents like levosimendan and serelaxin showing potential renoprotective benefits, while data for nitrates remain limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: